These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 38597264)

  • 21. Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia.
    Tron AE; Belmonte MA; Adam A; Aquila BM; Boise LH; Chiarparin E; Cidado J; Embrey KJ; Gangl E; Gibbons FD; Gregory GP; Hargreaves D; Hendricks JA; Johannes JW; Johnstone RW; Kazmirski SL; Kettle JG; Lamb ML; Matulis SM; Nooka AK; Packer MJ; Peng B; Rawlins PB; Robbins DW; Schuller AG; Su N; Yang W; Ye Q; Zheng X; Secrist JP; Clark EA; Wilson DM; Fawell SE; Hird AW
    Nat Commun; 2018 Dec; 9(1):5341. PubMed ID: 30559424
    [TBL] [Abstract][Full Text] [Related]  

  • 22. BH3-only proteins are dispensable for apoptosis induced by pharmacological inhibition of both MCL-1 and BCL-X
    Greaves G; Milani M; Butterworth M; Carter RJ; Byrne DP; Eyers PA; Luo X; Cohen GM; Varadarajan S
    Cell Death Differ; 2019 Jun; 26(6):1037-1047. PubMed ID: 30185825
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery of Potent Myeloid Cell Leukemia-1 (Mcl-1) Inhibitors That Demonstrate in Vivo Activity in Mouse Xenograft Models of Human Cancer.
    Lee T; Christov PP; Shaw S; Tarr JC; Zhao B; Veerasamy N; Jeon KO; Mills JJ; Bian Z; Sensintaffar JL; Arnold AL; Fogarty SA; Perry E; Ramsey HE; Cook RS; Hollingshead M; Davis Millin M; Lee KM; Koss B; Budhraja A; Opferman JT; Kim K; Arteaga CL; Moore WJ; Olejniczak ET; Savona MR; Fesik SW
    J Med Chem; 2019 Apr; 62(8):3971-3988. PubMed ID: 30929420
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recent Advances in the Development of Selective Mcl-1 Inhibitors for the Treatment of Cancer (2017-Present).
    Fan Y; Hou X; Fang H
    Recent Pat Anticancer Drug Discov; 2020; 15(4):306-320. PubMed ID: 32938354
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovery of β-carboline copper(II) complexes as Mcl-1 inhibitor and in vitro and in vivo activity in cancer models.
    Lu X; Liu YC; Orvig C; Liang H; Chen ZF
    Eur J Med Chem; 2019 Nov; 181():111567. PubMed ID: 31401535
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Small interfering RNA targeting mcl-1 enhances proteasome inhibitor-induced apoptosis in various solid malignant tumors.
    Zhou W; Hu J; Tang H; Wang D; Huang X; He C; Zhu H
    BMC Cancer; 2011 Nov; 11():485. PubMed ID: 22078414
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design, synthesis and biological evaluation of dual Bcl-2/Mcl-1 inhibitors bearing 2-(1H-indol-4-yl)benzoic acid scaffold.
    Niu Q; Deng H; Zhang Z; Xu Q; Luan S; Huang M; Liu D; Zhao L
    Bioorg Med Chem Lett; 2021 Sep; 47():128215. PubMed ID: 34153472
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax).
    Leverson JD; Zhang H; Chen J; Tahir SK; Phillips DC; Xue J; Nimmer P; Jin S; Smith M; Xiao Y; Kovar P; Tanaka A; Bruncko M; Sheppard GS; Wang L; Gierke S; Kategaya L; Anderson DJ; Wong C; Eastham-Anderson J; Ludlam MJ; Sampath D; Fairbrother WJ; Wertz I; Rosenberg SH; Tse C; Elmore SW; Souers AJ
    Cell Death Dis; 2015 Jan; 6(1):e1590. PubMed ID: 25590800
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Improved binding affinities of pyrrolidine derivatives as Mcl-1 inhibitors by modifying amino acid side chains.
    Wan Y; Liu T; Li X; Chen C; Fang H
    Bioorg Med Chem; 2017 Jan; 25(1):138-152. PubMed ID: 27810438
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interdiction at a protein-protein interface: MCL-1 inhibitors for oncology.
    Li K
    Bioorg Med Chem Lett; 2021 Jan; 32():127717. PubMed ID: 33253879
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovery of a Myeloid Cell Leukemia 1 (Mcl-1) Inhibitor That Demonstrates Potent
    Tarr JC; Salovich JM; Aichinger M; Jeon K; Veerasamy N; Sensintaffar JL; Arnhof H; Samwer M; Christov PP; Kim K; Wunberg T; Schweifer N; Trapani F; Arnold A; Martin F; Zhao B; Miriyala N; Sgubin D; Fogarty S; Moore WJ; Stott GM; Olejniczak ET; Engelhardt H; Rudolph D; Lee T; McConnell DB; Fesik SW
    J Med Chem; 2024 Aug; 67(16):14370-14393. PubMed ID: 39102508
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of Mcl-1 with the pan-Bcl-2 family inhibitor (-)BI97D6 overcomes ABT-737 resistance in acute myeloid leukemia.
    Pan R; Ruvolo VR; Wei J; Konopleva M; Reed JC; Pellecchia M; Andreeff M; Ruvolo PP
    Blood; 2015 Jul; 126(3):363-72. PubMed ID: 26045609
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacologic Targeting of Mcl-1 Induces Mitochondrial Dysfunction and Apoptosis in B-Cell Lymphoma Cells in a
    Liu T; Lam V; Thieme E; Sun D; Wang X; Xu F; Wang L; Danilova OV; Xia Z; Tyner JW; Kurtz SE; Danilov AV
    Clin Cancer Res; 2021 Sep; 27(17):4910-4922. PubMed ID: 34233959
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular analysis of functional redundancy among anti-apoptotic Bcl-2 proteins and its role in cancer cell survival.
    Eichhorn JM; Alford SE; Sakurikar N; Chambers TC
    Exp Cell Res; 2014 Apr; 322(2):415-24. PubMed ID: 24556425
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Myeloid cell leukemia-1 is an important apoptotic survival factor in triple-negative breast cancer.
    Goodwin CM; Rossanese OW; Olejniczak ET; Fesik SW
    Cell Death Differ; 2015 Dec; 22(12):2098-106. PubMed ID: 26045046
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Attacking cancer's Achilles heel: antagonism of anti-apoptotic BCL-2 family members.
    Opferman JT
    FEBS J; 2016 Jul; 283(14):2661-75. PubMed ID: 26293580
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sabutoclax (BI97C1) and BI112D1, putative inhibitors of MCL-1, induce mitochondrial fragmentation either upstream of or independent of apoptosis.
    Varadarajan S; Butterworth M; Wei J; Pellecchia M; Dinsdale D; Cohen GM
    Neoplasia; 2013 May; 15(5):568-78. PubMed ID: 23633928
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Key Survival Factor, Mcl-1, Correlates with Sensitivity to Combined Bcl-2/Bcl-xL Blockade.
    Williams MM; Lee L; Hicks DJ; Joly MM; Elion D; Rahman B; McKernan C; Sanchez V; Balko JM; Stricker T; Estrada MV; Cook RS
    Mol Cancer Res; 2017 Mar; 15(3):259-268. PubMed ID: 28039357
    [TBL] [Abstract][Full Text] [Related]  

  • 39. DRP-1 is required for BH3 mimetic-mediated mitochondrial fragmentation and apoptosis.
    Milani M; Byrne DP; Greaves G; Butterworth M; Cohen GM; Eyers PA; Varadarajan S
    Cell Death Dis; 2017 Jan; 8(1):e2552. PubMed ID: 28079887
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discovery of a Copper-Based Mcl-1 Inhibitor as an Effective Antitumor Agent.
    Lu X; Liu YC; Orvig C; Liang H; Chen ZF
    J Med Chem; 2020 Sep; 63(17):9154-9167. PubMed ID: 32794745
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.